History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies (i.e., antibodies with generic names ending in \ximab\ or \zumab\, respectively) or fusion proteins
Patients with a history of allergic reaction to irinotecan, cephalosporins or a severe penicillin allergy are not eligible
No known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
Prior history of allergic reactions to G-CSF
Prior history of allergic reactions to docetaxel and/or to medications formulated with polysorbate 80
Prior allergic reaction to the hormones involved in this protocol
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
The patient must NOT have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe hypersensitivity reactions to other mAbs
Patients allergic to eggs are not eligible
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component of CX-4945.
Patients with a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies are not eligible
History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments;
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies
Hx of drug-related anaphylactic reactions, severe allergic reactions related to drug; active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients who are allergic to milk
Have a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
Patient has a history of allergic reactions attributed to perillyl alcohol.
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
Must not have known allergic reaction against any of the components of the study treatment
Previous allergic reaction to an immunomodulatory drug (IMiD)
Use of steroids for non-tumor indications (for example: asthma or severe allergic reaction) is permitted
History of allergic reactions attributed to components of the formulated product
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Intolerance to or prior severe (?Grade 3) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab).
History of allergic reactions to any component of the IMP.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions attributed to cyclophosphamide or alemtuzumab
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides
Patients with severe allergic reactions to iodine contrast which cannot be controlled by premedication with antihistamines and steroids.
History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients may not have a history of allergic reaction or hypersensitivity to microcrystalline cellulose (Avicel PH302) or polysorbate 80 (Tween 80), which are components of the drug product MGCD516
EXCLUSION - INFUSION: History of allergic reactions attributed to nivolumab or any other checkpoint inhibitors
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reaction to docetaxel
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of anaphylactic allergic reactions attributed to agents used in study (i.e. doxirubicin, epirubicin, MRI contrast agents or iodinated contrast agents)
History of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Any history of allergic reaction to chemotherapies used
A history of serious allergic reactions, which in the opinion of the investigator pose an increased risk of serious infusion reactions.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to baker’s yeast, unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization
History of severe allergic reactions to vaccines or unknown allergens
History of allergic reactions to pralatrexate or romidepsin
Hypersensitivity (history of allergic reactions) to
History of allergic reactions or sensitivity to pyrimethamine
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;
History of allergic reaction to alpha-1-antitrypsin.
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of anaphylactic reaction to a recombinant protein or hypersensitivity to PEG
Patients with hypersensitivity or other allergic reaction to platinum chemotherapy.
Patients with hypersensitivity or other allergic reaction to taxanes.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
History of severe allergic reactions to humanized monoclonal antibodies
Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or non-steroidal antiinflammatory drugs (NSAIDs)
History of allergic reactions to either azacitidine or ascorbic acid
MEDICATION-RELATED: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins
History of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, nab-paclitaxel, avelumab)
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reaction (including erythema nodosum) to lenalidomide
Patients with history of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated product
Patients with history of allergic or toxic reactions attributed to anthracyclines or a history of allergic reactions to components of the formulated product
Allergic reaction to single-agent rucaparib or irinotecan
Prior allergic reaction or known intolerance to irinotecan
History of allergic reactions attributed to monoclonal antibodies (grade >= 3)
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients with intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the study drug (including excipients)
Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA)
History of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxel
If in Arm G, significant allergic reaction to cisplatin.
Prior allergic reaction to cisplatin
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients with a history of severe allergic reaction to cisplatin or carboplatin
History of allergic reactions to carboplatin or paclitaxel
(Atezolizumab-related exclusion) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions to SGI-110 or decitabine
History of, or suspected allergic reactions to durvalumab, pralatrexate, oral 5-azacitidine, or romidepsin or any of their excipients
History of severe allergic reactions (as determined by treating physician) attributed to the drugs being used in the study
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions to products containing mouse and bovine protein antibodies.
History of anaphylactic reaction to human, or humanized, antibody
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known allergic reactions, irritations or sensitivity to the active ingredients or other components of SOR007;
Patients with intolerance to or who have had a severe (>= grade 3) allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the investigational product (including excipients)
History of anaphylaxis or serious allergic reaction to carboplatin or paclitaxel
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
Patients with a history of an anaphylactic reaction to irinotecan.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
Patients with a history of allergic reactions attributed to docetaxel or paclitaxel are ineligible
Allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known severe allergic or other prohibitive reactions to other tyrosine kinase inhibitors (TKI)
History of severe allergic reactions to humanized monoclonal antibodies
Prior allergic reaction to cisplatin
History of allergic reaction to interleukin-2 or nivolumab
History of allergic reactions to TGR-1202 or carfilzomib
Patients must not have a history of severe allergic reactions (i.e., grade 4 allergy, anaphylactic reaction from which the subject did not recover within 6 hours of institution of supportive care) to any unknown allergens or any components of the nivolumab formulations
History of uncontrollable allergic reactions to bevacizumab or ascorbic acid
History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).
Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins are not eligible
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine, or study drugs involved in this protocol, or to a monoclonal antibody or prior hypersensitivity to platinum-containing agents
The subject has a history of serious allergic reaction to any substance, resulting in hospitalization or requiring other emergent medical attention
History of allergic reaction to DSF or Cu
History of anaphylactic reaction to human, or humanized, antibody
Any previous treatment with AZD1775 or allergic reactions to excipients of AZD1775
Patients with known potentially anaphylactic allergic reactions to gadolinium- diethylene triamine pentaacetic acid (DTPA)
Allergic to temozolomide (TMZ)
Patients who have experienced allergic reactions to monoclonal antibodies
History of allergic reaction to intravenous iodinated contrast media is not contraindication to the study; patients with history of mild allergic reaction to iodinated contrast media will be premedicated with 40 mg of prednisone orally (p.o.) 12 and 2 hours (hrs) before the transarterial chemoperfusion treatment to prevent allergic reaction; patients with history of moderate and severe allergic reaction to iodinated contrast media or patients with history of mild allergic reaction to iodinated contrast media despite adequate premedication will undergo angiogram using carbon dioxide or a gadolinium based contrast agent
History of severe hypersensitivity reactions to other mAbs
Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis
History of allergic reactions attributed to doxorubicin or Doxil.
History of uncontrollable allergic reactions to vitamin D
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
History of allergic reaction to natalizumab
Documented allergic reactions or similar to antibody treatments
Patients with a history of allergic reactions to filgrastim (GM-CSF) or the tetanus vaccine
No life-threatening allergy to baker’s yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin B
ELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Must not have a life-threatening allergy to baker’s yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin B
Propensity to allergic reactions defined as a history of allergic reaction to more than one medication
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Prior allergic reaction to the study drug(s) involved in this protocol
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Prior allergic reaction to temozolomide
Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents that prohibit the ability to complete the imaging requirements.
History of severe allergic reaction to sunitinib or valproic acid; inability to receive sunitinib or valproic acid
Prior allergic reaction to the hormones involved in this protocol
Patients with known history of allergic reaction to intravenous (IV) contrast material that is not amenable to pre-treatment by University of Alabama at Birmingham (UAB) protocol
The patient is allergic to naproxen or ibuprofen
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, Abraxane)
History of Grade 3 or higher allergic reaction with prior asparaginase treatment,
History of allergic reactions to recombinant IL-2
History of allergic reactions or intolerance to any of the required agents on the study
Previous history of anaphylaxis or severe allergic reaction to hsp110, gp100, other vaccines, or unknown allergens
Severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product
Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis
COHORT 3: ATOPIC DERMATITIS PATIENTS: Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine
COHORT 3: ATOPIC DERMATITIS PATIENTS: Known allergic reaction to sodium hypochlorite (NaOCl)
No prior known allergic reaction to monoclonal antibodies
History of >= 2 allergic reaction or any grade anaphylactic reaction during prior administration of tocilizumab
Patients with severe allergic reaction to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids (because a hepatic angiogram is needed for the Delcath system procedure).
History of severe hypersensitivity reactions to other mAbs
History of allergic reactions to study compounds or excepients Additional exclusion criteria Part A: Patients with clinically active brain metastases and prior exposure to AZD9150, AZD5069, MEDI4736, or any other anti PD (L)1 antibody.
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.
Previous allergic reaction to radioisotope bone tracers
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
Known history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysis
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known sensitivity or allergic reactions to acyclovir or valacyclovir
History of allergic reactions to mouse antigens
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component.
Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions to any components of the treatments
History of allergic reactions to cetuximab.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
Known allergic reaction to talimogene laherparepvec, paclitaxel, aromatase inhibitors, tamoxifen, fulvestrant, or any of their components; an exception is made if the patient will not be receiving the offending agent/component (i.e. a patient who is allergic to paclitaxel but will be receiving endocrine therapy is eligible)
History of any hypersensitivity or allergic reaction to any beta lactam antibiotic, tazobactam, or any study therapy (IV or oral)
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Allergic reaction/hypersensitivity to lenalidomide or history of anaphylactic shock to brentuximab vedotin in the past
Has prior allergic reaction or hypersensitivity to celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Has history of asthma, or other allergic-type reactions after taking aspirin or other NSAIDs
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of ? grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication
Prior allergic reaction to cetuximab
Participants with a history of allergic reactions attributed to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of allergic reactions to chemotherapy agents used in this protocol as part of lymphodepletion regimen (fludarabine and cyclophosphamide)
History of severe allergic reaction, including erythema nodosum, to lenalidomide
History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases
Patients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCI
History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases
History of allergic or idiosyncratic/hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
Patients who are allergic to micafungin and/or voriconazole or any of their ingredients
Documented severe allergic reaction to intravenous (IV) iodinated contrast, specifically bronchospasm and anaphylaxis
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions or intolerance to any of the required agents on the study
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Prior allergic reaction to cisplatin
Patients with any history of allergic reaction to paclitaxel or other taxanes or carboplatin
Prior allergic reaction to the study drug(s) involved in this protocol
History of clinically significant allergic reaction attributed to any injected\n             compound.
Known history of allergic reactions to paclitaxel
Prior allergic reaction to any of the study drugs involved in this protocol
History of allergic reactions attributed to riluzole or sorafenib
Prior allergic reaction to the study drug(s) involved in this protocol
History of anti-drug antibodies, severe allergic, anaphylactic, or other infusion-related reaction to a previous biologic agent
Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol
History of severe hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
Known allergy(ies) to any component of CMB305, atezolizumab, or severe allergic reactions to monoclonal antibodies, fusion proteins, or CHO cell products.
History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins.
History of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipients
For Combination Dose Finding and Combination Expansion cohorts only: history of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the lead principal investigator (PI)
Known allergic reaction to any component of MEDI1873
Prior allergic reaction to cetuximab
History of significant adverse or allergic reaction to any component of G100 and, if enrolled in Part 2, anti-PD1 antibodies.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs
Prior thalidomide is allowed, however, patients must not have prior >= grade-3 allergic reactions to thalidomide
Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin
History of allergic reactions to Cremophor EL, paclitaxel or its components
Prior allergic reaction to the study drugs.
Patients with prior grade 3 allergic or infusion reactions to docetaxel, cisplatin or cetuximab are not eligible; a history of well tolerated infusion reactions is NOT an exclusion
Prior allergic reaction to the study drugs involved in this protocol
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic reactions to any unknown allergens or any components of the study drugs
Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX-0158 formulation.
History of clinically significant allergic reactions or atopic disease that may pose an increased risk of severe CDX-0158 IRRs.
History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis
History of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Patients must not have known allergic reactions to GM-CSF or the tetanus vaccine
History of severe hypersensitivity reactions to other mAbs.
History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
Has prior allergic reaction to bevacizumab
History of allergic reaction to parenteral administered recombinant protein product
History of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
Patients with a history of grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of the anti-GD2 therapy are not eligible
History of allergic reactions to imiquimod or its excipients
Prior allergic reaction to the study drugs (cisplatin, mitomycin, fluorouracil [5FU]) involved in this protocol
History of severe allergic reactions to any unknown allergens or any components of the study drugs
Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin;
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager
History of solid organ transplantation and of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies
Prior allergic reactions attributed to other monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Prior allergic reaction to the drugs involved in this protocol
History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate dehydrate
History of severe allergic reactions to any unknown allergens or components of the study drugs.
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
Patients with a prior history of serious allergic reactions associated with thalidomide or lenalidomide
History of intolerance (including grade 3 or 4 infusion reactions) to murine proteins
Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA)
History of severe allergic or anaphylactic reactions to monoclonal antibodies
Patients with a history of allergic reactions attributed to eribulin or irinotecan
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Patients with history of allergic reaction to minocycline or to any of the tetracyclines
Prior allergic reaction to temozolomide
Prior allergic reaction to 5-FU or oxaliplatin
Prior allergic reaction or hypersensitivity to sulfonamides (may be allowed per investigator discretion based on patient history), celecoxib or NSAIDs
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic reactions to any unknown allergens or any components of the study drug formulations
History of uncontrollable allergic reactions to temozolomide or ascorbic acid or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Any previous treatment with LDE225 or allergic reactions to excipients of LDE225
History of allergic reaction or intolerance to statin treatment
History of an allergic reaction or intolerance to irinotecan
History of allergic reaction (including erythema nodosum) to lenalidomide
Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
History of allergic reactions attributed to thalidomide or lenalidomide
No history of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
History of allergic reactions to oral 5-azacitidine or romidepsin
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
History of allergic reactions attributed to fluoropyrimidine (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of serious allergic reactions to pegfilgrastim or filgrastim
History of allergic reaction to docetaxel
History of allergic reaction to disulfiram
Prior allergic reaction to temozolomide.
Prior allergic reaction to the study drug (bevacizumab)
Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.
History of allergic reactions to bacterially-produced proteins
History of allergic reactions to medicines containing polyoxyethylated castor oil that are not controlled with premedications
Hypersensitivity to the active substance or to any of the excipients for study drug BT062, or history of severe allergic or anaphylactic reaction to therapeutic proteins (e.g. reaction to vaccination or to biological therapy)
Known history of allergic reaction to cremophor/paclitaxel
History of allergic reactions attributed to trastuzumab (cohorts 1, 3) that were not treatable/preventable with pre-medications or desensitization protocols
Significant allergic reaction to iodinated contrast
Acute allergic disorders or a history of severe allergic reactions
History of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
Patients must not have known allergic reactions to GM-CSF
History of anaphylaxis or serious allergic reactions to previous administration of any of the vaccines
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis
History of allergic reactions to compounds containing boron, mannitol, VELCADE
Prior allergic reaction to the study drugs involved in this protocol
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or eribulin
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of allergic reactions attributed to fluoropyrimidines (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine
History of allergic reaction to ATRA
History of allergic reaction to dasatinib
Patients with a history of serious allergic reactions
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to any of the other study drugs
History of allergic reactions to monoclonal antibody therapy (or excipients in the formulation)
Previous life-threatening anaphylactic reactions to prior monoclonal antibody-based immunotherapy or any component of the moxetumomab pasudotox formulation
History of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
Intolerance to rituximab or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibodies
Patients who have experienced a previous grade 3 or 4 anaphylactic reaction to paclitaxel
History of allergic reaction to a structural compound or biological agent similar to TH-302
Prior allergic reaction to the study drug(s) involved in this protocol
History of severe allergic reactions to vaccines or unknown allergens.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic reactions to any unknown allergens or any components of the study drug formulations.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of serious allergic reaction to yeast or yeast-derived products, including known or suspected hypersensitivity reaction to sargramostim;
History of drug-related anaphylactic reactions or allergic reactions; subjects with an active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids will be excluded
History of anaphylactic reaction(s) to blood or blood components.
Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
Prior anaphylactic or severe hypersensitivity reaction to paclitaxel or Cremophor-containing agent.
History of allergic reactions attributed to components of the formulated product(s)
Known allergic reaction to neratinib, pertuzumab, trastuzumab, paclitaxel, or any of their components
History of allergic reactions to anilinoquinazolins like gefitinib, erlotinib, or BIBW2992
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
Transformation of CLL to aggressive B-cell malignancy History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides.
History of allergic or toxic reactions attributed to cytarabine (Part 2) or history of allergic reactions to components of the formulated product
History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein
Subjects with a history of allergic reactions to lactose.
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
Contraindication to steroid use or history of allergic reactions attributable to the study compounds
History of allergic reactions to bacterially-produced proteins
History of allergic reactions to monoclonal antibodies
History of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
History of an allergic reaction to Human Serum Albumin
History of allergic reactions to the study drugs, their analogs or any component of the products
Patient has a history of allergic reaction attributable to bortezomib or other compounds containing boron or mannitol (Phase 1b and 2a only)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.
History of allergic reactions to quinalones or chloroquine.
Patients with history of life threatening allergic reactions to food or drugs
Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy.
History of allergic reactions attributed to compounds chemically related to lapatinib (quinazolines), capecitabine, fluorouracil or any excipients;
The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (e.g., patients in whom dosing with obinutuzumab would be contraindicated for safety reasons)
History of allergic reactions attributed to:\r\n* Study agent or its metabolites\r\n* Iodinated contrast media
No history of previous severe allergic reactions to vaccines or unknown allergens
History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
Patients with known allergic reaction to lamivudine or tenofovir DF
Known allergic reaction to nickel
History of allergic reaction to ivabradine
Previous allergic reactions to dexamethasone.
Prior allergic reaction to bevacizumab or severe adverse event with bevacizumab.
History of severe hypersensitivity reactions to other mAbs.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
Patients with a history of allergic reaction to ropivacaine or other local amide anesthetics
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation
History of allergic reactions to whey or milk proteins
No history of (H/O) allergic reaction to iron therapy
Must not have a contraindication for using lidocaine: e.g. no history of allergic reactions to lidocaine
History of allergic reactions to whey protein
Subjects with history of allergic reactions to ketamine
Allergic to yogurt
History of drug sensitivity or allergic reaction to alpha- or beta-blockers
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation or to latex
Severe hypersensitivity reaction to apixaban, dalteparin, heparin or pork products (e.g., anaphylactic reactions)
History of allergic or other adverse reactions to minocycline
History of allergic or other adverse reactions to tetracycline
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of the anesthetics or analgesics medications used in the study
A history of allergic reactions attributed to either Monocryl suture or stainless steel staples
Previous allergic reactions to dexamethasone
Patients with severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product
Patient with known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts
Prior significant allergic reactions to drugs containing Cremophor, such as cyclosporine, or vitamin K are not eligible; a significant reaction may be defined as, but is not limited to, the description of grade  = 3 allergic reactions using the Common Toxicity Criteria (CTC)
Allergic reaction to carbamazepine or oxcarbazepine (major histocompatibility complex, class I, B [HLA-B]*1502)
History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
History of allergic or other adverse reaction to venlafaxine or SSRI’s
Patients with a history of a severe allergic reaction (anaphylaxis)
Participants who have a known severe allergic response to one or more allergens, as defined by anaphylaxis.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
History of drug sensitivity or allergic reaction to alpha or beta-blockers
Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
History of severe allergic reaction to obinutuzumab
Not be allergic to any cruciferous vegetables (e.g.: broccoli, cauliflower, kale, brussels sprouts, arugula/rocket, bok choy, etc.)
History of hypersensitivity or allergic reaction to NRT, or any component of its formulation
Evidence or history of clinically significant allergic reactions to varenicline
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
History of allergic reactions attributed to naproxen
Allergic reaction to omeprazole
Allergic reaction to vitamin D
Any known allergic reaction to vaccine components
History of allergic reactions or hypersensitivity to compounds similar to trastuzumab and/or letrozole
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
Patients with a known history of allergic reaction to ethanol, nitroglycerin, or citrate
Evidence or history of clinically significant allergic reactions to varenicline
life threatening allergic reaction to food and/or drugs
History of allergic reactions or hypersensitivity to ketamine
Known allergic reaction to gadopentetate dimeglumine (Gd-DTPA)
History of anaphylactic reactions or severe allergies
There will be no exclusion requirements due to co-morbid disease or incurrent illness\r\n* History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study
Since the diagnostic MR examination does not require injection of contrast agent there will be no specific requirements regarding history of allergic reactions
History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study
History of allergic reactions to gadolinium-based MRI contrast agent
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretion
Known allergic reactions to components of the study product(s)
Patients with a history of anaphylactic reactions to OTL38
Have had allergic response to contrast agents (such as iodine or gadolinium) previously
History of anaphylactic reaction to human, or humanized, antibody
Patients with renal failure or history of allergic reaction to Gadavist will be excluded
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretion
Participants who have a known severe allergic response to one or more allergens
Patients with contraindications to the use of intravenous contrast such as allergic type reactions
Known history of allergic reaction to magnetic resonance (MR) contrast material
Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
History of multiple or severe allergic reactions attributed to immunoglobulins or MRI contrast agents
Patients who are allergic to gadolinium based contrast agent
Known allergic reaction to diethylene triamine pentaacetic acid (Gd-DTPA)
Previous allergic reaction to contrast medium
Allergic reaction to iodine-containing contrast material
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion
Known allergic reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator’s discretion
Previous anaphylactic reaction to either FDHT or FDG
Allergic to common dentifrice ingredients
have been allergic to contrast agents;
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion
Patients with a history of allergic reaction to latex or gadolinium containing intravenous contrast agents
History of severe reactions (e.g. allergic, anaphylactic, or other hypersensitivity) to chimeric or humanized antibodies or fusion proteins
History of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to the chemotherapy drugs used in this study, unless the antibody can be given through a desensitization program in consultation with an allergist
History of severe allergic/hypersensitivity reaction or significant transfusion reaction.
Previous anaphylactic reaction to human, humanized or chimeric antibody
Severe allergic disease
PART B: Contra-indication to gadolinium contrast (e.g. chronic renal disease, prior allergic reaction) for patient studies
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator’s discretion)
Subjects who have experienced allergic or other adverse reactions in response to intravenous injection of fluorinated radiotracers and other contrast media used in PET/CT
Subjects who have had past allergic or other adverse reactions to intravenous injection of Magnevist® (gadopentetate dimeglumine) or other gadolinium-containing contrast agents
Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides
Subjects who have exhibited past allergic or other adverse reactions in response to intravenous injection of Magnevist (gadopentetate dimeglumine) or other gadolinium-containing contrast agents
No restrictions on allergic reactions as no imaging agent will be used
History of allergic reactions attributed to ICG or other agents used in the study, including known iodide or seafood allergy
Known prior allergic reaction to gadolinium-based magnetic resonance (MR) contrast agents
Previous anaphylactic reaction to huJ591 antibody or FDG imaging
History of allergic reaction to MR contrast media
History of allergic reactions attributed to 5 azacitidine
Patients may not have a history of severe allergic reactions to paclitaxel or other drugs formulated in cremaphor® EL
Participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in TAK-164 formulation.
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).
History of severe allergic-like reaction to iodinated contrast media
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).
History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization.
History of anaphylactic reactions or severe allergies
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
